Table 2.

Treatment details of patients with disease progression

Characteristic	n = 54 (100 %)
Primary tumour resection
Yes	45 (83.3 %)
No	9 (16.7 %)
No. of cycles
Median	10
(range)	(2–32)
Combined drug
Oxaliplatin	19 (35.2 %)
Irinotecan	35 (64.8 %)
Response to bevacizumab-based therapy
CR + PR	23 (42.6 %)
SD + PD	31 (57.4 %)

CR complete response, PR partial response, SD stable disease, PD progressive disease